
    
      The primary objective of this study is to assess the preliminary efficacy of up to three
      different dosage regimens of R788 as determined by ACR 20 responder rates at 12 weeks The
      secondary objectives of this study are to assess the safety of up to three different dosage
      regimens of R788 as determined by ACR 20 responder rates at 12 weeks, and to assess the
      general clinical and laboratory safety evaluations throughout the study.
    
  